Tango Therapeutics, Inc. (TNGX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$59.78M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$48.77M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $14.07M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$40.97M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$59.78M | (m) | (m) | (m) | -$20.00K* | -$38.87M* | (m) | $37.20M | (m) | $1.00K |
| 2026-03-31 | Reported | (m) | -$48.77M | (m) | (m) | (m) | -$2.00K | -$44.36M | (m) | $33.53M | (m) | $1.00K |
| 2025-09-30 | Reported | (m) | $14.07M | (m) | (m) | (m) | $151.00K* | -$30.95M* | (m) | $30.82M | (m) | -$10.00K |
| 2025-06-30 | Reported | (m) | -$40.97M | (m) | (m) | (m) | $624.00K* | -$36.52M* | (m) | $32.81M | (m) | $35.00K |
| 2025-03-31 | Reported | (m) | -$42.53M | (m) | (m) | (m) | $51.00K | -$41.70M | (m) | $36.44M | (m) | $34.00K |
| 2024-09-30 | Reported | (m) | -$32.88M | (m) | (m) | (m) | $115.00K* | -$33.39M* | (m) | $33.26M | (m) | $54.00K |
| 2024-06-30 | Reported | (m) | -$29.55M | (m) | (m) | (m) | $320.00K* | -$23.61M* | (m) | $38.65M | (m) | $65.00K |
| 2024-03-31 | Reported | (m) | -$42.26M | (m) | (m) | (m) | $195.00K | -$37.86M | (m) | $38.06M | (m) | $40.00K |
| 2023-09-30 | Reported | (m) | -$25.63M | (m) | (m) | (m) | $16.00K* | -$31.14M* | (m) | $27.15M | (m) | $23.00K |
| 2023-06-30 | Reported | (m) | -$23.25M | (m) | (m) | (m) | $664.00K* | -$24.47M* | (m) | $28.67M | (m) | $64.00K |
| 2023-03-31 | Reported | (m) | -$30.29M | (m) | (m) | (m) | $620.00K | -$34.91M | (m) | $28.04M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$29.92M | (m) | (m) | (m) | $3.28M* | -$19.61M* | (m) | $28.74M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$25.20M | (m) | (m) | (m) | $1.81M* | -$31.54M* | (m) | $23.74M | (m) | $3.00K |
| 2022-03-31 | Reported | (m) | -$25.38M | (m) | (m) | (m) | $1.56M | -$29.66M | (m) | $24.33M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$19.57M | (m) | (m) | (m) | $774.00K* | -$21.49M* | (m) | $21.92M | (m) | $62.00K |
| 2021-06-30 | Reported | (m) | -$4.56M | (m) | (m) | (m) | $202.00K* | -$7.52M* | (m) | $19.08M | (m) | -$21.00K |
| 2021-03-31 | Reported | (m) | -$12.08M | (m) | (m) | (m) | $165.00K | -$13.61M | (m) | $15.00M | (m) | $74.00K |
| 2020-09-30 | Reported | (m) | -$26.76M | (m) | (m) | (m) | (m) | (m) | (m) | $12.98M | (m) | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$111.29M | (m) | (m) | (m) | $1.05M | -$138.89M | (m) | $132.16M | (m) | $4.00K |
| 2024-12-31 | Reported | (m) | -$145.59M | (m) | (m) | (m) | $754.00K | -$131.50M | (m) | $143.92M | (m) | $208.00K |
| 2023-12-31 | Reported | (m) | -$114.17M | (m) | (m) | (m) | $1.53M | -$117.98M | (m) | $115.20M | (m) | $134.00K |
| 2022-12-31 | Reported | (m) | -$111.07M | (m) | (m) | (m) | $7.69M | -$109.08M | (m) | $105.91M | (m) | $54.00K |
| 2021-12-31 | Reported | (m) | -$58.19M | (m) | (m) | (m) | $1.84M | -$59.53M | (m) | $77.64M | (m) | $292.00K |
| 2020-12-31 | Reported | (m) | -$52.20M | (m) | (m) | (m) | $1.11M | $70.07M | (m) | $49.99M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |